4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Consensus Rating of “Moderate Buy” from Analysts

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) has been given an average rating of “Moderate Buy” by the eleven analysts that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $28.70.

Several brokerages recently issued reports on FDMT. Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Wednesday, October 8th. Morgan Stanley raised 4D Molecular Therapeutics from an “underweight” rating to an “equal weight” rating in a report on Friday, November 7th. Royal Bank Of Canada increased their target price on 4D Molecular Therapeutics from $26.00 to $32.00 and gave the stock an “outperform” rating in a report on Tuesday, November 11th. Barclays decreased their price target on 4D Molecular Therapeutics from $38.00 to $33.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 11th. Finally, Chardan Capital upped their price objective on shares of 4D Molecular Therapeutics from $25.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, November 11th.

Insider Activity

In related news, insider Scott Bizily sold 2,678 shares of 4D Molecular Therapeutics stock in a transaction that occurred on Friday, October 24th. The shares were sold at an average price of $12.00, for a total value of $32,136.00. Following the transaction, the insider directly owned 3,594 shares of the company’s stock, valued at $43,128. This trade represents a 42.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. In the last quarter, insiders have sold 10,763 shares of company stock worth $109,415. Company insiders own 9.60% of the company’s stock.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of FDMT. Armistice Capital LLC raised its holdings in shares of 4D Molecular Therapeutics by 265.3% during the 3rd quarter. Armistice Capital LLC now owns 1,096,000 shares of the company’s stock worth $9,524,000 after buying an additional 796,000 shares in the last quarter. Wexford Capital LP acquired a new position in 4D Molecular Therapeutics during the third quarter worth about $41,000. Prelude Capital Management LLC raised its stake in 4D Molecular Therapeutics by 11.1% during the third quarter. Prelude Capital Management LLC now owns 23,000 shares of the company’s stock worth $200,000 after acquiring an additional 2,300 shares in the last quarter. Parkman Healthcare Partners LLC bought a new position in shares of 4D Molecular Therapeutics in the third quarter worth about $1,738,000. Finally, Brevan Howard Capital Management LP acquired a new stake in shares of 4D Molecular Therapeutics in the 3rd quarter valued at approximately $143,000. Institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Stock Performance

NASDAQ:FDMT opened at $10.84 on Friday. 4D Molecular Therapeutics has a 52 week low of $2.23 and a 52 week high of $12.34. The firm’s 50-day simple moving average is $9.68 and its 200 day simple moving average is $6.51. The firm has a market cap of $619.34 million, a price-to-earnings ratio of -2.89 and a beta of 2.96.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its earnings results on Monday, November 10th. The company reported ($1.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.02) by $0.01. 4D Molecular Therapeutics had a negative net margin of 174,314.17% and a negative return on equity of 47.27%. The firm had revenue of $0.09 million for the quarter, compared to analyst estimates of $0.40 million. Sell-side analysts anticipate that 4D Molecular Therapeutics will post -2.84 EPS for the current year.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.